financetom
Business
financetom
/
Business
/
Evolent Health Insider Sold Shares Worth $1,070,798, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evolent Health Insider Sold Shares Worth $1,070,798, According to a Recent SEC Filing
Aug 29, 2024 2:38 AM

04:27 AM EDT, 08/27/2024 (MT Newswires) -- Daniel Joseph McCarthy, President, on August 22, 2024, sold 34,162 shares in Evolent Health ( EVH ) for $1,070,798. Following the Form 4 filing with the SEC, McCarthy has control over a total of 188,340 shares of the company, with 188,340 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1628908/000162890824000100/xslF345X05/wk-form4_1724717792.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Southwest Airlines ( LUV ) said in a regulatory filing Thursday that it increased its Q4 unit revenue growth forecast to a range of 5.5% to 7% from the previous range of 3.5% to 5.5%, citing better-than-expected leisure travel demand and revenue optimization efforts. The carrier said it now expects Q4 capacity to...
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
Dec 5, 2024
07:50 AM EST, 12/05/2024 (MT Newswires) -- CME Group ( CME ) said Thursday its board approved an annual variable dividend totaling $2.10 billion as well as a share repurchase program of up to $3 billion of Class A common stock. The dividend amounts to $5.80 per share and is payable Jan. 16, 2025, to shareholders of record as of...
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Patterson Companies ( PDCO ) reported fiscal Q2 adjusted earnings Thursday of $0.47 per diluted share, down from $0.50 a year earlier. A single analyst polled by FactSet expected $0.47. Net sales for the fiscal quarter ended Oct. 26 was $1.67 billion, up from $1.65 billion a year earlier. Analysts surveyed by FactSet...
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Dec 5, 2024
07:47 AM EST, 12/05/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it has started a late-stage clinical trial to assess investigational oral antiviral COVID-19 medicines Lagevrio or molnupiravir for the treatment of adults with COVID-19 who are at high risk for disease progression. Lagevrio is being developed by Merck ( MRK ) in collaboration with Ridgeback Biotherapeutics....
Copyright 2023-2026 - www.financetom.com All Rights Reserved